Stockreport

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Dupixent is a key top-line driver for both Sanofi and Regeneron, with strong demand trends. In the first nine months of 2024, Dupixent generated global product sales of [Read more]